BTAI insider filings
BioXcel Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen BTAI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BTAI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — BioXcel Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Atkins Susan E. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 219 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 17,500 · Sale (S): 6,560 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 49,758 · Sale (S): 19,419 @ $1.09 · Option exercise (M): 49,758 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 18,000 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Laumas Sandeep — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Bray June — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MACK DAVID J. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Votruba Michal — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Patni Rajiv — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MUELLER PETER — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MILLER MICHAEL PATRICK — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 199,032 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 163 · Option exercise (M): 219 · Option exercise (M): 163 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 15,625 | EDGAR |
| 2025-07-22 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 4,375 | EDGAR |
| 2025-07-22 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
Recent 8-K events — BioXcel Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-30 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-01 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership | EDGAR |
| 2026-08-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BTAI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs